CR20190290A - Composición mejorada de lansoprazol y simeticona y proceso para prepararla - Google Patents

Composición mejorada de lansoprazol y simeticona y proceso para prepararla

Info

Publication number
CR20190290A
CR20190290A CR20190290A CR20190290A CR20190290A CR 20190290 A CR20190290 A CR 20190290A CR 20190290 A CR20190290 A CR 20190290A CR 20190290 A CR20190290 A CR 20190290A CR 20190290 A CR20190290 A CR 20190290A
Authority
CR
Costa Rica
Prior art keywords
microgranules
simeticone
lansoprazole
concentration
preparing same
Prior art date
Application number
CR20190290A
Other languages
English (en)
Inventor
Esteban Alejandro Fiore
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of CR20190290A publication Critical patent/CR20190290A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica de administración oral, que comprende la combinación a dosis fija de Simeticona en microgránulos de alta concentración y Lansoprazol o su enantiómero (Dexlansoprazol) en microgránulos de liberación entérica y el proceso para obtener los microgránulos de alta concentración de Simeticona.The present invention relates to an orally administered pharmaceutical composition comprising a fixed-dose combination of simeticone in high-concentration microgranules and lansoprazole or the enantiomer thereof (dexlansoprazole) in enteric-release microgranules. The invention also relates to a method for obtaining the high-concentration simeticone microgranules.
CR20190290A 2016-12-14 2017-12-13 Composición mejorada de lansoprazol y simeticona y proceso para prepararla CR20190290A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2016016587A MX2016016587A (es) 2016-12-14 2016-12-14 Composicion mejorada de lansoprazol y simeticona y procesos para prepararla.
PCT/IB2017/057904 WO2018109693A1 (es) 2016-12-14 2017-12-13 Composición mejorada de lansoprazol y simeticona y proceso para prepararla

Publications (1)

Publication Number Publication Date
CR20190290A true CR20190290A (es) 2019-11-18

Family

ID=62558163

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190290A CR20190290A (es) 2016-12-14 2017-12-13 Composición mejorada de lansoprazol y simeticona y proceso para prepararla

Country Status (9)

Country Link
AR (1) AR110183A1 (es)
BR (1) BR112019011966A2 (es)
CL (1) CL2019001462A1 (es)
CO (1) CO2019006693A2 (es)
CR (1) CR20190290A (es)
DO (1) DOP2019000145A (es)
MX (1) MX2016016587A (es)
PE (1) PE20191654A1 (es)
WO (1) WO2018109693A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073384A (en) * 1989-10-19 1991-12-17 Valentine Enterprises, Inc. Maltodextrin/defoaming composition combinate
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
WO2008056200A1 (en) * 2006-11-10 2008-05-15 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of simethicone
EP2790676B1 (en) * 2011-12-14 2018-01-10 Disphar International B.V. Simethicone formulation

Also Published As

Publication number Publication date
BR112019011966A2 (pt) 2019-11-05
WO2018109693A1 (es) 2018-06-21
CO2019006693A2 (es) 2019-07-10
CL2019001462A1 (es) 2019-08-23
DOP2019000145A (es) 2019-08-15
MX2016016587A (es) 2018-06-13
AR110183A1 (es) 2019-03-06
PE20191654A1 (es) 2019-11-07

Similar Documents

Publication Publication Date Title
CU20190005A7 (es) Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico
BR112017008301A2 (pt) extratos de cannabis e métodos de sua preparação e uso
CL2017002817A1 (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
EA201791702A1 (ru) Терапевтические средства на основе гликанов и связанные с ними способы
CO2019000938A2 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos
PE20151301A1 (es) Formulaciones farmaceuticas resistentes a la manipulacion indebida
CL2017001026A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
EA201190161A1 (ru) Способ получения твердых лекарственных форм солифенацина и его фармацевтически приемлемых солей для перорального введения
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
CL2018003682A1 (es) Composición farmacéutica oral, que comprende un agente farmacéuticamente activo, al menos un polímero catiónico bioadhesivo y al menos dos polímeros aniónicos.
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
CL2020000601A1 (es) Composición farmacéutica.
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
CR20190290A (es) Composición mejorada de lansoprazol y simeticona y proceso para prepararla
ECSP19044926A (es) Composición mejorada de lansoprazol y simeticona y proceso para prepararla
UY37518A (es) Formas de dosificación de liberación modificada gastroretentivas para oprozomib y proceso para su fabricación
PE20160245A1 (es) Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion
CY1125762T1 (el) Νεα απο του στοματος σκευασματα βελινοστατης
BR112018074655A2 (pt) formulação injetável de fosnetupitant e método de fabricação de uma formulação
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
UY37413A (es) Formulaciones de liberación inmediata de oprozomib
CO2019008347A2 (es) Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla